These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19759524)

  • 1. Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy.
    Tan X; He W; Liu Y
    Kidney Int; 2009 Dec; 76(12):1248-57. PubMed ID: 19759524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment combining aliskiren with paricalcitol is effective against progressive renal tubulointerstitial fibrosis via dual blockade of intrarenal renin.
    Chung S; Kim S; Kim M; Koh ES; Shin SJ; Park CW; Chang YS; Kim HS
    PLoS One; 2017; 12(7):e0181757. PubMed ID: 28753620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy.
    Tan X; Li Y; Liu Y
    J Am Soc Nephrol; 2006 Dec; 17(12):3382-93. PubMed ID: 17082242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling.
    Tan X; Wen X; Liu Y
    J Am Soc Nephrol; 2008 Sep; 19(9):1741-52. PubMed ID: 18525004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Up-regulation of HSP47 in the mouse kidneys with unilateral ureteral obstruction.
    Moriyama T; Kawada N; Ando A; Yamauchi A; Horio M; Nagata K; Imai E; Hori M
    Kidney Int; 1998 Jul; 54(1):110-9. PubMed ID: 9648069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin D: a new hope for chronic kidney disease?
    Li M; Batuman V
    Kidney Int; 2009 Dec; 76(12):1219-21. PubMed ID: 19946310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A reduction of unilateral ureteral obstruction-induced renal fibrosis by a therapy combining valsartan with aliskiren.
    Wu WP; Chang CH; Chiu YT; Ku CL; Wen MC; Shu KH; Wu MJ
    Am J Physiol Renal Physiol; 2010 Nov; 299(5):F929-41. PubMed ID: 20685818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of TNFR1 and TNFR2 receptors in tubulointerstitial fibrosis of obstructive nephropathy.
    Guo G; Morrissey J; McCracken R; Tolley T; Klahr S
    Am J Physiol; 1999 Nov; 277(5):F766-72. PubMed ID: 10564241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy.
    Pang M; Ma L; Gong R; Tolbert E; Mao H; Ponnusamy M; Chin YE; Yan H; Dworkin LD; Zhuang S
    Kidney Int; 2010 Aug; 78(3):257-68. PubMed ID: 20520592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed administration of hepatocyte growth factor reduces renal fibrosis in obstructive nephropathy.
    Yang J; Liu Y
    Am J Physiol Renal Physiol; 2003 Feb; 284(2):F349-57. PubMed ID: 12529273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of mitochondria in paricalcitol-mediated cytoprotection during obstructive nephropathy.
    García IM; Altamirano L; Mazzei L; Fornés M; Molina MN; Ferder L; Manucha W
    Am J Physiol Renal Physiol; 2012 Jun; 302(12):F1595-605. PubMed ID: 22492946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of integrin-linked kinase attenuates renal interstitial fibrosis.
    Li Y; Tan X; Dai C; Stolz DB; Wang D; Liu Y
    J Am Soc Nephrol; 2009 Sep; 20(9):1907-18. PubMed ID: 19541809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed treatment with enalapril halts tubulointerstitial fibrosis in rats with obstructive nephropathy.
    Ishidoya S; Morrissey J; McCracken R; Klahr S
    Kidney Int; 1996 Apr; 49(4):1110-9. PubMed ID: 8691732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of exendin-4 on the intrarenal renin-angiotensin system and interstitial fibrosis in unilateral ureteral obstruction mice: Exendin-4 and unilateral ureteral obstruction.
    Le Y; Zheng Z; Xue J; Cheng M; Guan M; Xue Y
    J Renin Angiotensin Aldosterone Syst; 2016 Oct; 17(4):. PubMed ID: 27913661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contributions of angiotensin II and tumor necrosis factor-alpha to the development of renal fibrosis.
    Guo G; Morrissey J; McCracken R; Tolley T; Liapis H; Klahr S
    Am J Physiol Renal Physiol; 2001 May; 280(5):F777-85. PubMed ID: 11292619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cysteamine modulates oxidative stress and blocks myofibroblast activity in CKD.
    Okamura DM; Bahrami NM; Ren S; Pasichnyk K; Williams JM; Gangoiti JA; Lopez-Guisa JM; Yamaguchi I; Barshop BA; Duffield JS; Eddy AA
    J Am Soc Nephrol; 2014 Jan; 25(1):43-54. PubMed ID: 24009239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNF-alpha deficiency accelerates renal tubular interstitial fibrosis in the late stage of ureteral obstruction.
    Morimoto Y; Gai Z; Tanishima H; Kawakatsu M; Itoh S; Hatamura I; Muragaki Y
    Exp Mol Pathol; 2008 Dec; 85(3):207-13. PubMed ID: 18840428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aliskiren restores renal AQP2 expression during unilateral ureteral obstruction by inhibiting the inflammasome.
    Wang W; Luo R; Lin Y; Wang F; Zheng P; Levi M; Yang T; Li C
    Am J Physiol Renal Physiol; 2015 Apr; 308(8):F910-22. PubMed ID: 25694485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocyte growth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice.
    Yang J; Dai C; Liu Y
    J Am Soc Nephrol; 2002 Oct; 13(10):2464-77. PubMed ID: 12239235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Petchiether A attenuates obstructive nephropathy by suppressing TGF-β/Smad3 and NF-κB signalling.
    You YK; Luo Q; Wu WF; Zhang JJ; Zhu HJ; Lao L; Lan HY; Chen HY; Cheng YX
    J Cell Mol Med; 2019 Aug; 23(8):5576-5587. PubMed ID: 31211499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.